{"annotatable":{"parts":["s1v1","s2v1","s3v1","s4v1","s5v1","s6v1","s7v1","s8v1","s9v1","s10v1","s11v1","s12v1","s13v1","s14v1","s15v1","s16v1","s17v1","s18v1","s19v1","s20v1"]},"anncomplete":true,"sources":[],"metas":{"m_82":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_83":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_84":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_85":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_86":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_35":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}}},"entities":[{"classId":"e_109","part":"s1v1","offsets":[{"start":0,"text":"Randomized Placebo-Controlled"}],"coordinates":[{"x":"90.00","y":"132.42"},{"x":"304.90","y":"142.39"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_107","part":"s1v1","offsets":[{"start":1181,"text":"A randomized, placebo-controlled study"}],"coordinates":[{"x":"159.11","y":"433.15"},{"x":"320.19","y":"439.72"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_125","part":"s1v1","offsets":[{"start":1195,"text":"placebo-controlled"}],"coordinates":[{"x":"221.04","y":"433.15"},{"x":"296.02","y":"439.72"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_125","part":"s1v1","offsets":[{"start":1529,"text":"placebo denervation"}],"coordinates":[{"x":"386.96","y":"469.15"},{"x":"467.58","y":"475.72"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_125","part":"s1v1","offsets":[{"start":1583,"text":"placebo injections"}],"coordinates":[{"x":"207.71","y":"481.15"},{"x":"280.20","y":"487.72"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_125","part":"s1v1","offsets":[{"start":1912,"text":"placebo group"}],"coordinates":[{"x":"221.88","y":"535.24"},{"x":"278.81","y":"541.81"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_114","part":"s3v1","offsets":[{"start":1362,"text":"Studypatients were randomized in a 1:1 ratio to receive either true or placebo denervation. A researchnurse not involved in patient care performed randomization in blocks of 4 via pre-sealedenvelopes at each institution"}],"coordinates":[{"x":"492.46","y":"286.99"},{"x":"263.60","y":"329.56"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_125","part":"s3v1","offsets":[{"start":1433,"text":"placebo denervation"}],"coordinates":[{"x":"395.45","y":"298.99"},{"x":"475.52","y":"305.56"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_136","part":"s4v1","offsets":[{"start":601,"text":"In the control group, electrodes were similarly positioned, electrostimulation was performedin an identical manner, and 0.5 ml of lidocaine 2% was administered, but no current wasadministered. The average time it took to perform the radiofrequency and placebo procedureswere comparable (a mean of 61 minutes vs. 54 minutes, respectively, for the first 5 people ineach group)."}],"coordinates":[{"x":"150.00","y":"156.80"},{"x":"199.98","y":"211.37"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_190","part":"s4v1","offsets":[{"start":1034,"text":"A physician unaware of the patient’s study group assignment obtained all outcome data duringscheduled follow-up visits."}],"coordinates":[{"x":"150.00","y":"244.90"},{"x":"258.05","y":"263.47"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_185","part":"s4v1","offsets":[{"start":1034,"text":"A physician unaware of the patient’s study group assignment obtained all outcome data duringscheduled follow-up visits"}],"coordinates":[{"x":"150.00","y":"244.90"},{"x":"255.55","y":"263.47"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_180","part":"s4v1","offsets":[{"start":3116,"text":"The primary outcome measure was a 0–10 NRS pain score, which reflected the average painexperienced by the patient for 10 days prior to follow-up."}],"coordinates":[{"x":"150.00","y":"552.90"},{"x":"379.40","y":"571.47"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_216","part":"s4v1","offsets":[{"start":3116,"text":"The primary outcome measure was a 0–10 NRS pain score, which reflected the average painexperienced by the patient for 10 days prior to follow-up."}],"coordinates":[{"x":"150.00","y":"552.90"},{"x":"379.40","y":"571.47"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_152","part":"s5v1","offsets":[{"start":384,"text":"Statistical analyses were performed using STATA version 10.0 (Statcorp, College Station,TX). The Shapiro-Wilk W test for normal data was performed on continuous outcomemeasures. The distribution of categorical variables in each group was compared using Fisherexact test. Continuous variables are reported as mean and standard deviation or median andinterquartile range. Categorical data are reported by number of subjects and percentage.Comparisons between the initial radiofrequency treatment group and the placebo group weremade with unpaired t-tests or Mann-Whitney U test. Since the continuous data in each grouphad a normal distribution, comparisons between and within the initial radiofrequency andcrossover treatment groups were made with two-way analysis of variance (ANOVA). Formultiple significance testing, post-hoc Bonferroni correction was used. Because baseline ODIdifferences were a potential confounding factor, an adjusted multiple linear and logisticregression analysis was performed for each continuous and categorical outcome measure,respectively."}],"coordinates":[{"x":"150.00","y":"156.90"},{"x":"200.82","y":"307.47"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_159","part":"s5v1","offsets":[{"start":1470,"text":"Data were analyzed on 28 patients. Demographic (including active duty status) and clinicalcharacteristics were balanced between the radiofrequency denervation treatment and controlgroup. Two patients, one each in the control and treatment groups, received bilateralprocedures. Thirteen patients were taking opioids, and 24 were on non-opioid analgesics. Therewere no differences with regard to treatment location with the exception of military duty status,which was not present in those subjects treated at Johns Hopkins. Pre-procedure NRS scoresdid not appear to differ between the radiofrequency treatment and the placebo group (6.5 ± 1.9and 6.1 ± 1.8, respectively). However, preprocedural ODI scores did differ between thetreatment and placebo arms (37.1 ± 10.6 and 47.9 ± 9.3, respectively, table 1).Three patients in the placebo group declined to crossover to the radiofrequency denervationtreatment group. Among these 3 patients, one elected not to receive the true procedure becausethe placebo treatment was “too painful”, and 2 sought alternative care. Based on thedemographic and clinical characteristics, there appeared to be no difference between thesepatients and those who elected to cross-over."}],"coordinates":[{"x":"150.00","y":"362.98"},{"x":"329.13","y":"535.55"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_153","part":"s5v1","offsets":[{"start":1470,"text":"Data were analyzed on 28 patients. Demographic (including active duty status) and clinicalcharacteristics were balanced between the radiofrequency denervation treatment and controlgroup. Two patients, one each in the control and treatment groups, received bilateralprocedures. Thirteen patients were taking opioids, and 24 were on non-opioid analgesics."}],"coordinates":[{"x":"150.00","y":"362.98"},{"x":"497.09","y":"405.55"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_164","part":"s5v1","offsets":[{"start":1470,"text":"Data were analyzed on 28 patients. Demographic (including active duty status) and clinicalcharacteristics were balanced between the radiofrequency denervation treatment and controlgroup. Two patients, one each in the control and treatment groups, received bilateralprocedures. Thirteen patients were taking opioids, and 24 were on non-opioid analgesics."}],"coordinates":[{"x":"150.00","y":"362.98"},{"x":"497.09","y":"405.55"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_153","part":"s5v1","offsets":[{"start":2275,"text":"Three patients in the placebo group declined to crossover to the radiofrequency denervationtreatment group. Among these 3 patients, one elected not to receive the true procedure becausethe placebo treatment was “too painful”, and 2 sought alternative care. Based on thedemographic and clinical characteristics, there appeared to be no difference between thesepatients and those who elected to cross-over."}],"coordinates":[{"x":"150.00","y":"480.98"},{"x":"329.13","y":"535.55"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}}],"relations":[]}